Претраживање
Приказ резултата 1-5 од 5
Disease specific patient-reported outcome (pro) instruments for hematologic malignancies (hm)
(Elsevier Science Inc, New York, 2019)
Patient-reported outcomes used in clinical trials of systemic lupus erythematosus: a review of suitability for FDA labelling claims
(Elsevier Science Inc, New York, 2019)
A review of perfos in fda and ema labelling claims (2009-2019)
(Elsevier Science Inc, New York, 2019)
Overview of COA Measures in SLE Clinical Trials and Label Claims
(Elsevier, 2023)
Background
Systematic lupus erythematosus (SLE) is a condition linked with high symptom burden and severe quality of life (QoL) impacts. The FDA and EMA SLE guidance recommends inclusion of clinical outcome assessments ...
PCR43 A Review of Migraine-Related Pros in FDA Labelling Claims (2018-2023)
(Elsevier, 2023)
Objective
The objective of this review was to characterize the inclusion of migraine patient-reported outcomes (PROs) in FDA approvals subsequent the FDA’s release in 2018 of the Patient Focused Drug Development (PFDD) ...